3 reports

Two ocular SAEs were reported in the clinical program, one in Phase ## and one in Phase ##.

  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative
  • Amarantus BioScience Holdings, Inc.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Drug Discovery And Development
  • Ophthalmology
  • World
  • Product Initiative
  • Novartis AG

None of the nine control subjects followed was able to pass MT at one lux at year one.

  • Gene Therapy
  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative